Bioqube Ventures
Bioqube Ventures NV is a venture capital firm based in Brussels, Belgium, established in 2016. The company specializes in early-stage investments in the life sciences sector, particularly targeting European biotech companies that are developing innovative therapeutic assets and technologies. Bioqube Ventures focuses on investments in the Benelux countries, France, and Germany, aiming to advance scientific innovation and support companies with medicines in the testing phase. The firm employs a dual investment model that includes traditional early investment rounds and special attention to projects that require additional de-risking before launching new ventures. With a diverse team of fund managers, sector experts, and serial entrepreneurs, Bioqube Ventures takes a hands-on approach to drive growth and maximize value for its portfolio companies and investors.
Top Stages
13 past transactions
Commit Biologics
Seed Round in 2025
Commit Biologics is a biotechnology research company based in Aarhus, Denmark, established in 2021. The company specializes in developing an innovative immunotherapy platform aimed at treating various types of cancer. This platform utilizes bispecific domain antibodies to effectively target and eliminate tumor cells. Furthermore, it incorporates modular technology that enhances its ability to engage the body's innate immune response, thereby activating the complement component of the immune system. This approach not only focuses on cancer treatment but also has potential applications in addressing autoimmune diseases.
SynOx Therapeutics
Series B in 2024
SynOx Therapeutics is a clinical stage biopharmaceutical company based in Dublin, Ireland, established in 2019. The company focuses on the development of innovative therapies for cancer, particularly through its lead product, emactuzumab. This humanized monoclonal antibody specifically targets the CSF-1 receptor, aiming to deplete macrophages within tumor tissues. SynOx Therapeutics is dedicated to addressing the unmet clinical needs of patients suffering from diffuse tenosynovial giant cell tumors and other conditions associated with macrophage activity, ultimately striving to provide best-in-class treatment options that enhance patient quality of life. The company is backed by experienced investors with a strong track record in biopharmaceutical development.
Catalym
Series D in 2024
Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.
Commit Biologics
Seed Round in 2024
Commit Biologics is a biotechnology research company based in Aarhus, Denmark, established in 2021. The company specializes in developing an innovative immunotherapy platform aimed at treating various types of cancer. This platform utilizes bispecific domain antibodies to effectively target and eliminate tumor cells. Furthermore, it incorporates modular technology that enhances its ability to engage the body's innate immune response, thereby activating the complement component of the immune system. This approach not only focuses on cancer treatment but also has potential applications in addressing autoimmune diseases.
SynOx Therapeutics
Series B in 2024
SynOx Therapeutics is a clinical stage biopharmaceutical company based in Dublin, Ireland, established in 2019. The company focuses on the development of innovative therapies for cancer, particularly through its lead product, emactuzumab. This humanized monoclonal antibody specifically targets the CSF-1 receptor, aiming to deplete macrophages within tumor tissues. SynOx Therapeutics is dedicated to addressing the unmet clinical needs of patients suffering from diffuse tenosynovial giant cell tumors and other conditions associated with macrophage activity, ultimately striving to provide best-in-class treatment options that enhance patient quality of life. The company is backed by experienced investors with a strong track record in biopharmaceutical development.
Anavo Therapeutics
Seed Round in 2023
Anavo Therapeutics is a pioneering company focused on drugging phosphatases, a category of targets that has been deemed undruggable for many years. By leveraging world-class scientific expertise in phosphatase-driven disease biology and drug discovery, Anavo aims to develop innovative therapeutic programs, particularly in oncology. The company is advancing multiple first-in-class therapies and seeks to establish a robust pipeline across various indications through strategic partnerships. Anavo's work in this area seeks to unlock the potential of phosphatase-targeted allosteric modulators, offering new avenues for treatment in diseases where traditional approaches have fallen short.
Enhanc3D Genomics
Series A in 2022
Enhanc3D Genomics is a biotechnology firm focused on functional genomics, specifically examining the three-dimensional organization of DNA and its implications in health and disease. The company has developed the GenLink3D platform, which facilitates large-scale analysis of genetic variations and gene function by providing high-resolution profiles of genome folding for all genes and their enhancers simultaneously. This innovative technology enables researchers to understand the impact of genetic mutations on distant genes, thereby elucidating their role in disease progression. By advancing knowledge in this area, Enhanc3D Genomics supports the development of novel drug therapies aimed at addressing significant unmet medical needs.
Tridek-One
Venture Round in 2022
Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at addressing auto-immune and inflammatory disorders. The company's primary product is a peptide designed to maintain a cluster of truncated CD31 molecules at the membrane, which helps moderate overactive immune responses without complete blockade. By facilitating improved treatment options for medical companies, Tridek-One seeks to enhance the quality of life for patients suffering from these conditions.
Egle Therapeutics
Series A in 2021
Egle Therapeutics SAS is a biotechnology company founded in 2020 and based in Paris, France. The company specializes in developing immunotherapies aimed at targeting immune suppressor regulatory T-cells (Tregs) to address oncology and autoimmune diseases. Egle Therapeutics is focused on its proprietary pipeline, which includes a series of computationally designed IL-2 variants designed to modulate Tregs by either engaging or disengaging them from tumor environments. Through its innovative approach to Treg modulation, the company aims to enable healthcare professionals to develop new therapies that effectively target these immune suppressor cells, potentially transforming treatment options for cancer and other diseases.
Anavo Therapeutics
Seed Round in 2021
Anavo Therapeutics is a pioneering company focused on drugging phosphatases, a category of targets that has been deemed undruggable for many years. By leveraging world-class scientific expertise in phosphatase-driven disease biology and drug discovery, Anavo aims to develop innovative therapeutic programs, particularly in oncology. The company is advancing multiple first-in-class therapies and seeks to establish a robust pipeline across various indications through strategic partnerships. Anavo's work in this area seeks to unlock the potential of phosphatase-targeted allosteric modulators, offering new avenues for treatment in diseases where traditional approaches have fallen short.
Primmune Therapeutics
Series A in 2021
Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists aimed at enhancing innate immunity for cancer immunotherapy. Its TLR7 agonists are designed to stimulate the immune system by producing cytokines and chemokines that boost cellular responses and activate natural killer cells. This approach is intended to complement existing cancer treatments, such as checkpoint inhibitors, improving overall response rates and treatment durability. Primmune Therapeutics' innovative therapies target both acute and chronic viral infections, as well as metastatic diseases, while also promoting B-cell proliferation and activation.
Enhanc3D Genomics
Seed Round in 2021
Enhanc3D Genomics is a biotechnology firm focused on functional genomics, specifically examining the three-dimensional organization of DNA and its implications in health and disease. The company has developed the GenLink3D platform, which facilitates large-scale analysis of genetic variations and gene function by providing high-resolution profiles of genome folding for all genes and their enhancers simultaneously. This innovative technology enables researchers to understand the impact of genetic mutations on distant genes, thereby elucidating their role in disease progression. By advancing knowledge in this area, Enhanc3D Genomics supports the development of novel drug therapies aimed at addressing significant unmet medical needs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.